Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Malmö University Hospital Swedish Cancer Society Europe Against Cancer (European Union Directorate General XII- Public Health) |
---|---|
Information provided by: | Malmö University Hospital |
ClinicalTrials.gov Identifier: | NCT00479375 |
Human papillomavirus (HPV)-based cervical screening is known to increase sensitivity for detection of high-grade cervical intraepithelial neoplasia (CIN). Randomized trials of longitudinal efficacy are required to assess whether these gains represent overdiagnosis or a protective effect.
Methods: A total of 12527 women, aged 32-38, attending population-based invitational screening in Sweden were randomized 1:1 to HPV test and cytology (intervention arm) or cytology only (control arm). HPV-positive women were invited for a second HPV test at least one year later and women with type-specific persistent infections were then invited to colposcopy. A similar number of random double-blinded procedures are performed in the control arm. Women are followed with comprehensive registry-based follow-up. Primary outcome is the relative rates of CIN grade 2 or worse (CIN2/CIN3+) found in subsequent screening. Secondary outcomes are the relative rates of CIN2/CIN3+ found in the aseline screening and outcomes stratified by grade of CIN (CIN 2 or CIN3+).
Condition | Intervention |
---|---|
Cervical Cancer Cervical Intraepithelial Neoplasia |
Procedure: Adding Human Papillomavirus testing to organised cervical screening |
Study Type: | Interventional |
Study Design: | Screening, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Randomized Controlled Trial of Human Papillomavirus Testing in Primary Cervical Screening |
Enrollment: | 12527 |
Study Start Date: | May 1997 |
Study Completion Date: | May 2007 |
Ages Eligible for Study: | 32 Years to 38 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Sweden | |
Malmo University Hospital | |
Malmo, Sweden, SE-20502 |
Principal Investigator: | Joakim Dillner, MD | Malmo University Hospital, Lund University |
Study ID Numbers: | 3824-B00-05XAC |
Study First Received: | May 25, 2007 |
Last Updated: | May 25, 2007 |
ClinicalTrials.gov Identifier: | NCT00479375 History of Changes |
Health Authority: | Sweden: Regional Ethical Review Board |
screening human papillomavirus |
Carcinoma in Situ Neoplasms, Glandular and Epithelial Carcinoma Cervical Intraepithelial Neoplasia |
Neoplasms Neoplasms by Histologic Type Carcinoma in Situ |
Neoplasms, Glandular and Epithelial Carcinoma Cervical Intraepithelial Neoplasia |